| Bioactivity | Setrusumab (BPS 804) is a fully humanized monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer[1]. |
| In Vivo | Setrusumab (100 mg/kg；每周一次，静脉注射，持续 4 周) 抑制小鼠乳腺癌诱导的骨转移和肌肉无力[1]。 Animal Model: |
| Name | Setrusumab |
| CAS | 1847394-95-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hesse E, et al. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019 Apr 9;5(9):e125543. |